AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 21 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer -- Combining the bacillus Calmette-Guerin (BCG) vaccine for tetanus with a vaccine for diphtheria, pertussis, and tetanus shows promise, according to a new report in Infection and Immunity.
BCG, a weakened strain of Mycobacterium bovis and long used as a vaccine carrier for tuberculosis, was considered an ideal candidate as a live carrier for other vaccines.
"We analyzed the potential of CRM197, a mutated nontoxic derivative of diphtheria toxin, as the recombinant antigen for a BCG-based vaccine against diphtheria," said E.N. Miyaji and colleagues.
The research team found that using the recombinant BCG (rBCG) vaccine alone was not enough. When mice were immunized with rBCG CRM197, they developed antibodies to diphtheria toxin, but were unable to neutralize the toxin. When the CRM197 vaccine was given with BCG that expressed tetanus toxin fragment C (FC), however, the mice were able to neutralize diphtheria toxin ("Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM197, a mutant diphtheria toxin," Infection and Immunity, 2001;69(2):869-874).
Further analysis of this response revealed that using the BCG with tetanus toxin FC when delivering ...